Bicocca Open Archive

Logo unimib boa
MANTOVANI, LORENZO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.553
AS - Asia 18.558
EU - Europa 15.372
SA - Sud America 2.753
AF - Africa 338
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 38
Totale 64.678
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.908
SG - Singapore 7.360
IT - Italia 3.851
CN - Cina 3.838
HK - Hong Kong 3.282
RU - Federazione Russa 2.887
BR - Brasile 2.250
DE - Germania 2.096
VN - Vietnam 2.041
IE - Irlanda 1.537
SE - Svezia 1.457
GB - Regno Unito 756
UA - Ucraina 733
FR - Francia 489
CA - Canada 427
ID - Indonesia 382
FI - Finlandia 372
IN - India 357
AT - Austria 282
NL - Olanda 220
AR - Argentina 207
TR - Turchia 195
DK - Danimarca 183
BD - Bangladesh 179
KR - Corea 171
MX - Messico 149
ZA - Sudafrica 135
IQ - Iraq 106
PL - Polonia 103
JP - Giappone 96
ES - Italia 84
PK - Pakistan 81
IR - Iran 78
EC - Ecuador 65
AU - Australia 54
MA - Marocco 53
BE - Belgio 51
CO - Colombia 48
VE - Venezuela 48
SA - Arabia Saudita 46
CH - Svizzera 45
UZ - Uzbekistan 37
AE - Emirati Arabi Uniti 36
CL - Cile 36
PY - Paraguay 35
CZ - Repubblica Ceca 33
PH - Filippine 32
RO - Romania 32
EU - Europa 30
KE - Kenya 29
EG - Egitto 27
MY - Malesia 27
PE - Perù 25
JO - Giordania 23
TW - Taiwan 23
TH - Thailandia 21
BO - Bolivia 20
TN - Tunisia 20
AL - Albania 19
BG - Bulgaria 18
UY - Uruguay 18
ET - Etiopia 17
LT - Lituania 17
NG - Nigeria 17
IL - Israele 16
OM - Oman 15
PT - Portogallo 15
NP - Nepal 14
RS - Serbia 14
CR - Costa Rica 13
LB - Libano 13
DZ - Algeria 12
JM - Giamaica 12
GR - Grecia 11
KZ - Kazakistan 11
NO - Norvegia 11
NZ - Nuova Zelanda 11
MD - Moldavia 10
LK - Sri Lanka 9
AZ - Azerbaigian 8
BH - Bahrain 8
HN - Honduras 8
HU - Ungheria 8
QA - Qatar 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
KW - Kuwait 7
BB - Barbados 6
TT - Trinidad e Tobago 6
A2 - ???statistics.table.value.countryCode.A2??? 5
GE - Georgia 5
HR - Croazia 5
LU - Lussemburgo 5
LV - Lettonia 5
MK - Macedonia 5
NI - Nicaragua 5
PA - Panama 5
PS - Palestinian Territory 5
SI - Slovenia 5
SN - Senegal 5
Totale 64.609
Salva come PNG Salva come JPEG
Città #
Singapore 3.772
Ann Arbor 3.738
Hong Kong 3.261
Ashburn 2.242
Fairfield 1.958
Woodbridge 1.678
Chandler 1.435
Dublin 1.433
Houston 1.238
Frankfurt am Main 1.224
Wilmington 1.176
Santa Clara 1.037
Milan 932
Seattle 871
New York 853
Jacksonville 738
Beijing 705
Princeton 665
Cambridge 662
Dearborn 640
Ho Chi Minh City 611
Dallas 499
Hanoi 474
Los Angeles 411
Hefei 399
Jakarta 318
Altamura 302
The Dalles 298
Lawrence 292
Moscow 285
Nanjing 267
São Paulo 232
Vienna 210
Chicago 205
Buffalo 188
Shanghai 186
Rome 177
Helsinki 168
Council Bluffs 164
San Diego 155
Hangzhou 151
Seoul 150
Munich 144
Guangzhou 138
London 135
Nuremberg 134
Boardman 122
Toronto 108
Lachine 104
Shenyang 103
Andover 100
Dong Ket 100
Nanchang 96
Saint Petersburg 87
Rio de Janeiro 81
Jinan 79
Fremont 76
Tianjin 75
Tokyo 74
Columbus 72
Salt Lake City 72
Changsha 70
Hebei 70
Lappeenranta 66
Warsaw 65
Haiphong 64
Menlo Park 63
Bologna 61
Da Nang 61
Norwalk 59
Jiaxing 58
Brooklyn 56
Zhengzhou 56
San Jose 55
Falls Church 53
Ottawa 53
Brasília 50
Johannesburg 50
Montreal 48
Boston 47
Ningbo 46
Ninh Bình 46
Mexico City 45
Redmond 44
Phoenix 43
Poplar 43
Biên Hòa 42
Orem 42
Dhaka 41
Porto Alegre 40
Washington 40
Denver 39
Florence 39
Tampa 39
Turin 39
Belo Horizonte 38
Thái Nguyên 38
Brussels 37
Pune 37
Atlanta 36
Totale 40.219
Salva come PNG Salva come JPEG
Nome #
Costi dell’infarto miocardico acuto: analisi di dati sanitari amministrativi 914
Epidemiology of SLE in Italy: an observational study using a primary care database 497
Burden of Stroke in Europe: An Analysis of the Global Burden of Disease Study Findings from 2010 to 2019 480
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 445
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry 429
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 427
Administrative databases as a tool for identifying healthcare demand and costs in an over-one million population 416
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 400
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 398
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study 372
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 369
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 353
Distribution of Malocclusion Traits in the Pediatric Population of Milan: An Observational Study 343
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 336
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation 335
Inflammatory bowel diseases in italy: incidence trends and patients’ characteristics 326
Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis 325
Use of health care administrative databases to estimate the burden of breast cancer. 324
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 318
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 315
Magnitude and time-course of excess mortality during COVID-19 outbreak: population-based empirical evidence from highly impacted provinces in northern Italy 315
Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF 315
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 315
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 312
Utilization, Outcomes and Costs of Implantable Cardioverter Defibrillators in Italy: A Population-Based Analysis Using Healthcare Administrative Databases 310
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study) 310
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? 307
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 304
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 300
Occupational exposure in the lombardy region (Italy) to sars-cov-2 infection: Results from the mustang–occupation–covid-19 study 300
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 282
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 277
Health related quality of life in chronic liver diseases 277
Incidence and risk factors for falls among nursing home residents in Italy: a retrospective cohort study 274
Global, regional, and national burden of suicide mortality 1990 to 2016: Systematic analysis for the Global Burden of Disease Study 2016 270
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 265
Costs and effectiveness of influenza vaccination: A systematic review 262
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 261
Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 258
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 255
The socioeconomic burden of patients affected by hemophilia with inhibitors 253
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 251
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 250
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 249
Treatment of venous thromboembolism with tinzaparin in oncological patients 249
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 248
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 248
Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy 247
The impact of liver disease on the health-related quality of life 246
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 244
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 244
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 244
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 243
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 241
Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry 241
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 239
Impatto clinico ed economico della gestione dei rialzi pressori in gravidanza in regime di pronto soccorso: il possibile ruolo dei marcatori biochimici 238
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 237
Health Related Quality of Life in the Major Liver Conditions 236
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 235
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 234
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 232
Sustainability of the Italian National Health Service 231
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 227
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 227
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 226
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 226
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities 225
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry 223
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis 222
Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019 220
Medical Costs And Resources Consumption In Patients With Atrial Fibrillation: An Italian Observational Study 219
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 218
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 217
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 217
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 216
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 214
Persistence and adherence to hypolipemic therapy in real practice: Results of a large administrative database 213
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 213
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 212
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 212
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 212
Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019 211
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 211
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America 211
The economic impact of air pollution: a European assessment 211
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 209
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity 209
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 208
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 208
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 207
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 207
Difference in health related quality of life of chronic liver diseases and general population 207
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 205
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 205
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 205
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 203
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation 203
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: Co-medication interactions 203
Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016 202
Totale 27.355
Salva come PNG Salva come JPEG
Categoria #
all - tutte 242.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.896 0 0 0 0 0 615 699 682 567 512 363 458
2021/20223.998 321 391 400 360 275 301 196 248 234 295 280 697
2022/20236.447 781 1.873 536 518 455 977 74 355 480 93 182 123
2023/20245.455 171 247 185 271 681 1.299 859 195 525 158 235 629
2024/202515.484 811 1.811 751 740 1.251 943 818 477 1.648 1.911 1.570 2.753
2025/202616.276 3.810 2.017 2.264 2.971 3.467 1.747 0 0 0 0 0 0
Totale 66.781